The ICIs are only monoclonal antibodies targeting and blocking the co-inhibitory signals of either programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte antigen-4 (CTLA-4)—which are cytotoxic T cell surface receptors—or a ligand of PD-1 (PD-L1) from tumor cells or antigen-presenting cells [12]. This evidence concerns the gene CD274 and neoplasm.